Browsing Tag
CDMO
40 posts
Resonetics closes Resolution Medical deal, targeting full-stack dominance in neuromodulation and structural heart
Resonetics completes acquisition of Resolution Medical, adding biosimulation and finished device assembly to its neuromodulation and structural heart platform. Read the full analysis.
FUJIFILM Biotechnologies names former Rentschler Biopharma COO as Chief Business Officer ahead of global capacity ramp
FUJIFILM Biotechnologies appoints Christiane Bardroff as CBO from June 2026. What her hire signals for the CDMO's eight billion dollar capacity push. Read more.
Astec LifeSciences (ASTEC) reports narrowed Q3 loss as CDMO momentum drives positive EBITDA
Astec LifeSciences posts ₹125.5 crore in Q3 FY26 revenue with positive EBITDA. Find out how CDMO gains and margin recovery are reshaping the outlook today.
Bajaj Healthcare (NSE: BAJAJHCARE) Q3 FY26 earnings: API exports double, PAT up 34%
Bajaj Healthcare’s API exports doubled in Q3 FY26, driving 31% revenue growth. Find out what its CNS pipeline and CDMO ramp mean for future expansion.
GSK offloads Human Genome Sciences: what’s next for Samsung Biologics’ global ambitions?
Samsung Biologics acquires Human Genome Sciences from GSK for $280M, gaining its first U.S. biologics plant. Find out what this move means for global CDMO strategy.
Anupam Rasayan (NSE: ANURAS) set to acquire Jayhawk Fine Chemicals for $150m
Anupam Rasayan India acquires Jayhawk Fine Chemicals for $150M, expanding its global specialty chemicals footprint. Find out how this deal is reshaping the sector.
What Mitchell Rock’s appointment as CEO could mean for UFP Technologies’ strategy
UFP Technologies appoints President Mitchell Rock as CEO from June 2026, ending R. Jeffrey Bailly’s 31-year tenure. Find out what this leadership shift means.
SeQuent Scientific (NSE: SEQUENT) and Viyash Lifesciences merger gets NCLT approval, setting stage for India’s largest animal health platform
With over ₹16,462 million in H1 FY26 revenue and significant margin expansion, the newly combined entity is positioning itself as a top-tier global player in the animal health and pharmaceutical contract development space
BioHarvest Sciences completes nearly $20m financing round — what it means for shareholders and future growth
Find out how BioHarvest Sciences’ $19.9 million public offering is shaping its expansion plans, investor sentiment, and biotech growth outlook today.
Can Salvador Montes help Elevaris Medical Devices build a global operational edge in precision medtech?
Elevaris Medical Devices appoints Salvador Montes to lead global engineering and operations strategy. Learn how this move positions the CDMO for agile growth.